Author Archives: davidrcurry

Genomic epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely collected surveillance data

Posted on by

Lancet Global Health
Dec 2021 Volume 9 Number 12 e1623-e1769
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Genomic epidemiology and the role of international and regional travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely collected surveillance data
Tapfumanei Mashe, et al. on behalf of the COVID-19 Genomics UK Consortium, and the SARS-CoV-2 Research Group

Progress in reaching unvaccinated (zero-dose) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys

Posted on by

Lancet Global Health
Dec 2021 Volume 9 Number 12 e1623-e1769
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Progress in reaching unvaccinated (zero-dose) children in India, 1992–2016: a multilevel, geospatial analysis of repeated cross-sectional surveys
Mira Johri, Sunil Rajpal, S V Subramanian
Summary
Background
Reaching zero-dose children (infants who receive no routine vaccinations) is a global strategic priority. We studied zero-dose children in India over 24 years to clarify aggregate trends and the contribution of large-scale social, economic, and geographical inequalities to these.
Methods
We did a multilevel, geospatial analysis of repeated cross-sectional surveys of all four rounds (1992–2016) of India’s National Family Health Survey to study the prevalence, distribution, and drivers of zero-dose (no first dose of diphtheria, tetanus, and pertussis) vaccination status. We included all children born to participating women who were aged 12–23 months at the time of the survey, as this is the standard age at which immunisation data are assessed. Children who died before the survey and those missing data on key outcomes or correlates were excluded. The outcome was child zero-dose vaccination status. We also compared the prevalence of nutritional deficits among zero-dose versus vaccinated children. For the most recent survey, we produced geospatial estimates identifying the prevalence of zero-dose children across states and districts and used these to project head count.
Findings
We examined 393 167 children for eligibility. 72 848 children were included in the final analytic data set. The proportion of zero-dose children in India declined from 33·4% (95% CI 32·5–34·2) in 1992 to 10·1% (9·8–10·4) in 2016. Progress notwithstanding, in 2016, zero-dose children remained concentrated among disadvantaged groups (prevalence in the bottom wealth quintile 15·3%, 95% CI 14·6–16·0; prevalence among mothers with no education 16·8%, 16·1–17·4). Compared with vaccinated children, zero-dose children were more likely to suffer from malnutrition in all survey rounds (prevalence of severe stunting in 1992: zero dose 41·3%, 95% CI 39·2–43·8 vs vaccinated 28·5%, 27·2–29·7; 2016: zero dose 24·9%, 23·6–26·2 vs vaccinated 18·7%, 18·3–19·1). In 2016, there were an estimated 2·88 (95% CI 2·86–2·89) million zero-dose children in India, concentrated in less developed states and districts and several urban areas.
Interpretation
Over a 24-year period in India, child zero-dose status was shaped by large-scale social inequalities and remained a consistent marker of generalised vulnerability. Interventions that address this cycle of intergenerational inequities should be prioritised.

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Posted on by

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial
Bihua Han, et al.

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Posted on by

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
Shipo Wu, et al.

Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial

Posted on by

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial
Paul R Chapman, et al.

Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review

Posted on by

Lancet Infectious Diseases
Dec 2021 Volume 21 Number 12 p1613-1758, e363-e406
https://www.thelancet.com/journals/laninf/issue/current

 

Review
Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review
Anna Deal, et al. in collaboration with the European Society of Clinical Microbiology and Infectious Diseases Study Group for Infections in Travellers and Migrants (ESGITM)

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan

Posted on by

Lancet Respiratory Medicine
Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
Szu-Min Hsieh, et al.

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study

Posted on by

Lancet Respiratory Medicine
Dec 2021 Volume 9 Number 12 p1343-1478, e110-e122
https://www.thelancet.com/journals/lanres/issue/current

 

COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
Utkarsh Agrawal, et al.

The biological and clinical significance of emerging SARS-CoV-2 variants

Posted on by

Nature Reviews Genetics
Volume 22 Issue 12, December 2021
https://www.nature.com/nrg/volumes/22/issues/12

 

Review Article | 17 September 2021
The biological and clinical significance of emerging SARS-CoV-2 variants
In this Review, the authors describe our latest understanding of the emergence and properties of SARS-CoV-2 genetic variants, particularly those designated as WHO (World Health Organization) ‘variants of concern’. They focus on the consequences of these variants for antibody-mediated virus neutralization, with important implications for reinfection risk and for vaccine effectiveness.
Kaiming Tao, Philip L. Tzou, Robert W. Shafer

Lessons from vaccine-induced immune thrombotic thrombocytopenia

Posted on by

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Comment | 18 October 2021
Lessons from vaccine-induced immune thrombotic thrombocytopenia
Here, John Kelton and colleagues provide an overview of vaccine-induced immune thrombotic thrombocytopenia (VITT), a very rare complication that has been observed following vaccination with adenoviral vector-based COVID-19 vaccines.
John Greenhow Kelton, Donald Mitchell Arnold, Ishac Nazy

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?

Posted on by

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Progress | 19 October 2021
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Individuals with asymptomatic COVID-19 can transmit the virus and may be at risk of long-term disease. In this Progress article, Boyton and Altman present current insights into immune responses in asymptomatic SARS-CoV-2 infection and discuss the relevance of asymptomatic disease for public health strategies.
Rosemary J. Boyton, Daniel M. Altmann

Using cross-species vaccination approaches to counter emerging infectious diseases

Posted on by

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Perspective | 17 June 2021
Using cross-species vaccination approaches to counter emerging infectious diseases
Emerging diseases that affect humans often arise due to the crossover of infectious agents from animal reservoirs. In this Perspective, George Warimwe and colleagues discuss the concept of ‘One Health vaccinology’, an approach that aims to use key lessons from human and veterinary immunology to develop more effective vaccination strategies for emerging infectious diseases.
George M. Warimwe, Michael J. Francis, Bryan Charleston

Lessons from the elimination of poliomyelitis in Africa

Posted on by

Nature Reviews Immunology
Volume 21 Issue 12, December 2021
https://www.nature.com/nri/volumes/21/issues/12

 

Perspective | 25 October 2021
Lessons from the elimination of poliomyelitis in Africa
This Perspective chronicles the journey to the elimination of transmission of wild poliovirus in Africa, with a critical discussion of the global, continental, national and community actions that were required and the lessons learnt along the way.
Abdulaziz Mohammed, Oyewale Tomori, John N. Nkengasong

Engineering living therapeutics with synthetic biology

Posted on by

Nature Reviews Drug Discovery
Volume 20 Issue 12, December 2021
https://www.nature.com/nrd/volumes/20/issues/12

 

Review Article | 06 October 2021
Engineering living therapeutics with synthetic biology
The design of cell-based therapeutics with synthetic biology is a rapidly growing strategy in medicine for the development of effective treatments for a variety of diseases. This article discusses advances in synthetic biology approaches to programme living cells with therapeutic functions as well as challenges for their development.
Andres Cubillos-Ruiz, Tingxi Guo, Jose M. Lora

Will Africans take COVID-19 vaccination?

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Research Article
Will Africans take COVID-19 vaccination?
AbdulAzeez A. Anjorin, Ismail A. Odetokun, Ajibola I. Abioye, Hager Elnadi, Mfon Valencia Umoren, Bamu F. Damaris, Joseph Eyedo, Haruna I. Umar, Jean B. Nyandwi, Mena M. Abdalla, Sodiq O. Tijani, Kwame S. Awiagah, Gbolahan A. Idowu, Sifeuh N. Achille Fabrice, Aala M. O. Maisara, Youssef Razouqi, Zuhal E. Mhgoob, Salim Parker, Osaretin E. Asowata, Ismail O. Adesanya, Maureen A. Obara, Shameem Jaumdally, Gatera F. Kitema, Taofik A. Okuneye, Kennedy M. Mbanzulu, Hajj Daitoni, Ezekiel F. Hallie, Rasha Mosbah, Folorunso O. Fasina
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260575

Peer- and community-led responses to HIV: A scoping review

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Peer- and community-led responses to HIV: A scoping review
George Ayala, Laurel Sprague, L. Leigh-Ann van der Merwe, Ruth Morgan Thomas, Judy Chang, Sonya Arreola, Sara L. M. Davis, Aditia Taslim, Keith Mienies, Alessandra Nilo, Lillian Mworeko, Felicita Hikuam, Carlos Garcia de Leon Moreno, José Antonio Izazola-Licea
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260555

To vaccinate or not to vaccinate!? Predictors of willingness to receive Covid-19 vaccination in Europe, the U.S., and China

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

To vaccinate or not to vaccinate!? Predictors of willingness to receive Covid-19 vaccination in Europe, the U.S., and China
Julia Brailovskaia, Silvia Schneider, Jürgen Margraf
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260230

Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system
George N. Ioannou, Pamela Green, Emily R. Locke, Kristin Berry
Research Article | published 01 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0259696

Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

Psychological predictors of vaccination intentions among U.S. undergraduates and online panel workers during the 2020 COVID-19 pandemic
Suryaa Gupta, Shoko Watanabe, Sean M. Laurent
Research Article | published 30 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0260380

COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation

Posted on by

PLoS One
http://www.plosone.org/
[Accessed 4 Dec 2021]

 

COVID-19 vaccine confidence and hesitancy among health care workers: A cross-sectional survey from a MERS-CoV experienced nation
Mazin Barry, Mohamad-Hani Temsah, Abdullah Alhuzaimi, Nurah Alamro, Ayman Al-Eyadhy, Fadi Aljamaan, Basema Saddik, Ali Alhaboob, Fahad Alsohime, Khalid Alhasan, Abdulkarim Alrabiaah, Ali Alaraj, Rabih Halwani, Amr Jamal, Sarah Alsubaie, Fatimah S. Al-Shahrani, Ziad A. Memish, Jaffar A. Al-Tawfiq
Research Article | published 29 Nov 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0244415

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

Posted on by

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 4 Dec 2021]

 

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
Chris Davis, Nicola Logan, Grace Tyson, Richard Orton, William T. Harvey, Jonathan S. Perkins, Guy Mollett, Rachel M. Blacow, The COVID-19 Genomics UK (COG-UK) Consortium , Thomas P. Peacock, Wendy S. Barclay, Peter Cherepanov, Massimo Palmarini, Pablo R. Murcia, Arvind H. Patel, David L. Robertson, John Haughney, Emma C. Thomson, Brian J. Willett, on behalf of the COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators
Research Article | published 02 Dec 2021 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010022

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials

Posted on by

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 4 Dec 2021]

 

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
Stephanie Fischinger, Deniz Cizmeci, Davy Deng, Shannon P. Grant, Nicole Frahm, Julie McElrath, Jonathan Fuchs, Pierre-Alexandre Bart, Giuseppe Pantaleo, Michael Keefer, William O. Hahn, Nadine Rouphael, Gavin Churchyard, Zoe Moodie, Yeycy Donastorg, Hendrik Streeck, Galit Alter
Research Article | published 29 Nov 2021 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1010016

Opinion: Toward inclusive global governance of human genome editing

Posted on by

PNAS – Proceedings of the National Academy of Sciences of the United States
November 23, 2021; vol. 118 no. 47
https://www.pnas.org/content/118/47

 

Front Matter
Opinion: Toward inclusive global governance of human genome editing
Hanzhi Yu, Lan Xue, Rodolphe Barrangou, Shaowei Chen, and Ying Huang
PNAS November 23, 2021 118 (47) e2118540118
https://doi.org/10.1073/pnas.2118540118

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Posted on by

Science
Volume 374| Issue 6572| 3 Dec 2021
https://www.science.org/toc/science/current

 

Research Articles
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
BY Rishi R. Goel, et al.
03 Dec 2021
Open Access
Blood analysis of individuals vaccinated with the Moderna SARS-CoV-2 mRNA vaccine reveals distinct trajectories of immune memory responses.

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Posted on by

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Editorial Full text access
Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic
Alfonso J. Rodríguez-Morales, D. Katterine Bonilla-Aldana, José Antonio Suárez, Carlos Franco-Paredes, … Alberto Paniz-Mondolfi
Article 102192

Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes

Posted on by

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Research article Full text access
Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes
Clotilde El Guerche-Séblain, Lina Chakir, Gopinath Nageshwaran, Rebecca C. Harris, … Philippe Vanhems
Article 102171

A novel semi-quantitative methodology for national poliovirus reintroduction and outbreak risk assessment

Posted on by

Travel Medicine and Infectious Diseases
Volume 44 November–December 2021
https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/44/suppl/C

 

Research article Open access
A novel semi-quantitative methodology for national poliovirus reintroduction and outbreak risk assessment
Hendrik S. Camphor, Christina Bareja, Anna Glynn-Robinson, Benjamin G. Polkinghorne, David N. Durrheim
Article 102181

Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Discussion Full text access
Supporting use of thermostable vaccines during public health emergencies: Considerations and recommendations for the future
Divya Hosangadi, Elena K. Martin, Matthew Watson, Richard Bruns, Nancy Connell
Pages 6972-6974

Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Abstract only
Influenza vaccination uptake among high-risk target groups and health care workers in Spain and change from 2017 to 2020
Sara Sanz-Rojo, Rodrigo Jiménez-García, Ana López-de-Andrés, Javier de Miguel-Diez, … José J. Zamorano-León
Pages 7012-7020

COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Full text access
COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study
Helena C. Maltezou, Periklis Panagopoulos, Flora Sourri, Theodoros V. Giannouchos, … Dimitrios Hatzigeorgiou
Pages 7021-7027

Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Full text access
Changes in COVID-19 vaccine acceptance rate among recovered critically Ill patients: A 12-month follow-up study
Titilope Olanipekun, Temidayo Abe, Valery Effoe, Gloria Westney, Richard Snyder
Pages 7074-7081

Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Open access
Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study
Maria Esterlita T. Villanueva-Uy, Hilton Y. Lam, Josephine G. Aldaba, Tristan Marvin Z. Uy, … Clint Pecenka
Pages 7091-7100

Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)

Posted on by

Vaccine
Volume 39, Issue 48 Pages 6969-7116 (26 November 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/48

 

Research article Open access
Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch)
Thomas Byrne, Parth Patel, Madhumita Shrotri, Sarah Beale, … Richard Gilson
Pages 7108-7116

Pre-Print Servers

Posted on by

Pre-Print Servers

 

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 4 Dec 2021]

No new digest content identified.

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…
[Accessed 4 Dec 2021]
Selected Content
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Francisco Hernandez-Bernal, Maria del Carmen Ricardo-Cobas, Yenima Martin-Bauta, Zadis Navarro-Rodriguez, Marjoris Pinera-Martinez, Joel Quintana-Guerra, Karen Urrutia-Perez, Klaudia Urrutia-Perez, Cristina Olimpia Chavez-Chong, Jorge Luis Azor-Hernandez, Jose Luis Rodriguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Avila, Jacqueline Bizet-Almeida, Jeniffer Rodriguez-Nuviola, Sergio del Valle-Pinera, Mayara Ramirez-Dominguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdes, Gilda Lemos-Perez, Gerardo Enrique Guillen-Nieto, Ariel Palenzuela-Diaz, Enrique Noa-Romero, Miladys Limonta-Fernandez, Juan Manuel Fernandez-Avila, Nabil Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Avila, Verena Lucila Muzio-Gonzalez
medRxiv 2021.11.30.21267047; doi: https://doi.org/10.1101/2021.11.30.21267047 Revision

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
Douglas Lake, Alexa J Roeder, Maria J Gonzalez-Moa, Megan Koehler, Erin Kaleta, Paniz Jasbi, John Vanderhoof, Davis Mckechnie, Jack Forman, Baylee Edwards, Alim Seit-Nebi, Sergei Svarovsky
medRxiv 2021.11.30.21266716; doi: https://doi.org/10.1101/2021.11.30.21266716

The Politics of Vaccine Hesitancy in the United States
Jian Cao, Christina Ramirez, R. Michael Alvarez
medRxiv 2021.12.01.21267160; doi: https://doi.org/10.1101/2021.12.01.21267160

Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: a modeling study.
Clement R Massonnaud, Jonathan Roux, Vittoria Colizza, Pascal Crepey
medRxiv 2021.12.01.21267122; doi: https://doi.org/10.1101/2021.12.01.21267122

Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. Cities
S. Michael Gaddis, Colleen M. Carey, Nicholas V DiRago
medRxiv 2021.12.01.21267158; doi: https://doi.org/10.1101/2021.12.01.21267158

Assessing the Burden of COVID-19 in Developing Countries: Systematic Review, Meta-Analysis, and Public Policy Implications
Andrew T Levin, Nana Owusu-Boaitey, Sierra Pugh, Bailey K Fosdick, Anthony B. Zwi, Anup Malani, Satej Soman, Lonni Besançon, Ilya Kashnitsky, Sachin Ganesh, Aloysius McLaughlin, Gayeong Song, Rine Uhm, Gideon Meyerowitz-Katz
medRxiv 2021.09.29.21264325; doi: https://doi.org/10.1101/2021.09.29.21264325

Convalescent plasma for outpatients with early COVID-19
Pere Millat-Martinez, Arvind Gharbharan, Andrea Alemany, Casper Rokx, Corine GeurtsvanKessel, Grigorios Papageourgiou, Nan van Geloven, Carlijn Jordans, Geert Groeneveld, Francis Swaneveld, Ellen van der Schoot, Marc Corbacho-Monne, Dan Ouchi, Francini Piccolo Ferreira, Pierre Malchair, Sebastian Videla, Vanesa Garcia Garcia, Anna Ruiz-Comellas, Anna Ramirez-Morros, Joana Rodriguez Codina, Rosa Amado Simon, Joan-Ramon Grifols, Julia Blanco, Ignacio Blanco, Jordi Ara, Quique Bassat, Bonaventura Clotet, Barbara Baro, Andrea Troxel, Jaap Jan Zwaginga, Oriol Mitja, Bart Rijnders
medRxiv 2021.11.30.21266810; doi: https://doi.org/10.1101/2021.11.30.21266810

Google Trends as a predictive tool for COVID-19 vaccinations in Italy: a retrospective infodemiological analysis
Alessandro Rovetta
medRxiv 2021.11.29.21267012; doi: https://doi.org/10.1101/2021.11.29.21267012

The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
Nasikarn Angkasekwinai, Suvimol Niyomnaitham, Jaturong Sewatanon, Supaporn Phumiamorn, Kasama Sukapirom, Sansnee Senawong, Surakameth Mahasirimongkol, Zheng Quan Toh, Pinklow Umrod, Thitiporn Somporn, Supaporn Chumpol, Kanokphon Ritthitham, Kulkanya Chokephaibulkit
medRxiv 2021.11.29.21266947; doi: https://doi.org/10.1101/2021.11.29.21266947

Critical success factors for routine immunization performance: A case study of Zambia 2000 to 2018
Katie Rodriguez, Kyra A. Hester, Chama Chanda, Roopa Darwar, Bonheur Dounebaine, Anna S. Ellis, Pinar Keskinocak, Abimbola Leslie, Mwangala Manyando, Maurice Sililo Manyando, Dima Nazzal, Emily Awino Ogutu, Zoe Sakas, Francisco Castillo-Zunino, William Kilembe, Robert A. Bednarczyk, Matthew C. Freeman, the Vaccine Exemplars Research Consortium
medRxiv 2021.11.30.21267060; doi: https://doi.org/10.1101/2021.11.30.21267060

Use of Artificial Intelligence on spatio-temporal data to generate insights during COVID-19 pandemic: A Review
Gihan Jayatilaka, Jameel Hassan, Umar Marikkar, Rumali Perera, Suren Sritharan, Harshana Weligampola, Mevan Ekanayake, Roshan Godaliyadda, Parakrama Ekanayake, Vijitha Herath, G M Dilshan Godaliyadda, Anuruddhika Rathnayake, Samath D. Dharmaratne, Janaka Ekanayake
medRxiv 2020.11.22.20232959; doi: https://doi.org/10.1101/2020.11.22.20232959

Wellcome Open Research [to 4 Dec 2021]
https://wellcomeopenresearch.org/browse/articles
[Accessed 4 Dec 2021]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics Revised
10-year longitudinal study of malaria in children: Insights into acquisition and maintenance of naturally acquired immunity [version 2; peer review: 2 approved with reservations]
John W.G. Addy, Yaw Bediako, Francis M. Ndungu, John Joseph Valetta, Adam J. Reid, Jedida Mwacharo, Joyce Mwongeli Ngoi, Joshua Wambua, Edward Otieno, Jennifer Musyoki, Khadija Said, Matthew Berriman, Kevin Marsh, Philip Bejon, Mario Recker, Jean Langhorne
Peer Reviewers Rodrigo M Corder; Rhea J Longley
Funders: Wellcome Trust; Francis Crick Institute; Medical Research Council
LATEST VERSION PUBLISHED 03 Dec 2021

Data Note metrics Revised
The Avon Longitudinal Study of Parents and Children – A resource for COVID-19 research: Home-based antibody testing results, October 2020. An emphasis on self-screening at a population level [version 2; peer review: 1 approved, 2 approved with reservations]
Kate Northstone, Daniel Smith, Claire Bowring, Amanda Hill, Richard Hobbs, Nicholas Wells, Nicholas J. Timpson
Peer Reviewers Morteza Taheri; Jean-Luc Murk; Citra N.Z. Mattar
Funders: Wellcome Trust; Medical Research Council
LATEST VERSION PUBLISHED 02 Dec 2021

Open Letter metrics Revised
An ethical analysis of vaccinating children against COVID-19: benefits, risks, and issues of global health equity [version 2; peer review: 1 approved, 1 approved with reservations]
Rachel Gur-Arie, Steven R. Kraaijeveld, Euzebiusz Jamrozik
Peer Reviewers Stefan David Baral; Tracy Beth Høeg
Funders: Wellcome Trust; ZonMw
LATEST VERSION PUBLISHED 29 Nov 2021
Abstract
COVID-19 vaccination of children has begun in various high-income countries with regulatory approval and general public support, but largely without careful ethical consideration. This trend is expected to extend to other COVID-19 vaccines and lower ages as clinical trials progress. This paper provides an ethical analysis of COVID-19 vaccination of healthy children. Specifically, we argue that it is currently unclear whether routine COVID-19 vaccination of healthy children is ethically justified in most contexts, given the minimal direct benefit that COVID-19 vaccination provides to children, the potential for rare risks to outweigh these benefits and undermine vaccine confidence, and substantial evidence that COVID-19 vaccination confers adequate protection to risk groups, such as older adults, without the need to vaccinate healthy children. We conclude that child COVID-19 vaccination in wealthy communities before adults in poor communities worldwide is ethically unacceptable and consider how policy deliberations might evolve in light of future developments.